Hexarelin vs GHRP-6: Two Potent GH Secretagogues Compared
Here is how these two compounds compare — based on published research, not marketing claims.
Hexarelin
311
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
GHRP-6
778
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
Hexarelin and GHRP-6 are both powerful growth hormone secretagogues from the GHRP family. Neither is selective like ipamorelin — both raise cortisol and prolactin alongside GH. The interesting difference: hexarelin has been studied for cardiac protective effects. GHRP-6 produces stronger appetite stimulation. Both are potent but come with trade-offs.
Key Differences
| Attribute | Hexarelin | GHRP-6 |
|---|---|---|
| Evidence Level | Human Trials | Animal Studies |
| Category | GHRP | GHRP |
| Human Data | Multiple human pharmacodynamic studies. Cardiac protection data in humans. PSI rates L3. | Multiple human studies, primarily pharmacodynamic. Used as a GH stimulation agent. PSI rates L2. |
| Safety Profile | Raises cortisol and prolactin. Potential cardiac benefits are under investigation. Not FDA-approved. | Significant appetite increase. Raises cortisol and prolactin. Used clinically in research settings. |
| Key Limitations | Non-selective. Cortisol/prolactin elevation. GH response may diminish with repeated use (tachyphylaxis). | Strong appetite stimulation limits clinical applicability. Non-selective. Less human outcome data than hexarelin. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
Hexarelin
Activates ghrelin receptors to produce strong GH release. Also stimulates cortisol and prolactin. Uniquely, hexarelin has shown cardiac protective effects independent of GH — it may protect heart tissue directly.
GHRP-6
Activates ghrelin receptors with strong GH-releasing potency. Also powerfully stimulates appetite — more than any other GHRP. Raises cortisol and prolactin.
Same receptor family, different pharmacological profiles. Both activate GHS-R1a to release GH. Hexarelin appears to have additional cardiac receptor activity that GHRP-6 does not — it binds to CD36 receptors on cardiac tissue, potentially providing direct cardioprotection independent of GH. GHRP-6 has stronger orexigenic (appetite-stimulating) effects.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 1,089 indexed studies. Here are the key findings.
Hexarelin is L3 with more human data, particularly the cardiac protection research. GHRP-6 is L2 with solid pharmacodynamic data but less clinical depth. Hexarelin's cardiac angle gives it a unique research niche.
For GH stimulation with cardiac research interest, hexarelin has unique data.
For appetite stimulation (e.g., underweight patients), GHRP-6 has the strongest orexigenic effect.
For minimizing side effects, neither is ideal — consider ipamorelin instead.
For research on GH release potency, both are established tools.
Key Limitations
- •No direct head-to-head clinical trial.
- •Both are non-selective with off-target hormone effects.
- •Hexarelin's cardiac benefits need larger confirmatory trials.
- •GHRP-6's appetite effect limits its use in obesity-related applications.
PSI Verdict
SUPPORTED BY EVIDENCE
Both produce strong GH release through ghrelin receptor activation. Hexarelin demonstrates cardiac protective effects in human studies independent of GH elevation. GHRP-6 is an established GH stimulation test agent with consistent pharmacodynamic data.
NOT YET ESTABLISHED
Whether hexarelin's cardiac benefits are clinically meaningful at practical doses needs larger trials. GHRP-6's neuroprotective and hepatoprotective effects are primarily preclinical.
CONFIDENCE LEVEL
Moderate. Hexarelin has the edge for research interest due to its cardiac data. GHRP-6 has the edge for raw GH stimulation potency and appetite effects. Neither is the best choice if selectivity matters — ipamorelin fills that role.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Hexarelin
"Hexarelin is the strongest GH releaser available"Supported by evidence
"Hexarelin protects the heart directly"Supported by evidence
GHRP-6
"GHRP-6 is the strongest appetite stimulant of all the GH peptides"Supported by evidence
"GHRP-6 has anti-aging benefits beyond just GH"Plausible but limited human data
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
Hexarelin
Raises cortisol and prolactin. Potential cardiac benefits are under investigation. Not FDA-approved.
GHRP-6
Significant appetite increase. Raises cortisol and prolactin. Used clinically in research settings.
Both raise cortisol and prolactin. GHRP-6 causes more appetite increase. Hexarelin may cause tachyphylaxis (diminished response) with chronic use. Neither has an ideal side effect profile for long-term use.
WHAT THE RESEARCH SUGGESTS
Hexarelin has the more interesting research profile due to its cardiac data. GHRP-6 has more total publications but a worse side effect profile. For pure GH stimulation, both work. For a secondary benefit, hexarelin's cardiac angle is unique.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.